Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 2/20 | 0.54 |
| ▸ | CFD | P00746 | 4/20 | 0.53 |
| ▸ | TPSB2 | P20231 | 4/20 | 0.53 |
| ▸ | F11 | P03951 | 3/20 | 0.53 |
| ▸ | PLG | P00747 | 1/20 | 0.53 |
| ▸ | PLAU | P00749 | 1/20 | 0.53 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.53 |
| ▸ | F7 | P08709 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.45 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6747740 | 0.84 | APP (0.50) | AGXTMAPTMAPK1TDP1L3MBTL1 | |
| SCHEMBL74678 | 0.84 | MAPT (0.59) | MAPTMAPK1TDP1L3MBTL1FFAR1 | |
| SCHEMBL15326084 | 0.75 | MRGPRX4 (0.54) | AGXTCFDTPSB2F11PLG | |
| SCHEMBL27656865 | 0.75 | FFAR1 (0.49) | MAPTMAPK1TDP1L3MBTL1FFAR1 | |
| SCHEMBL21408110 | 0.74 | NR4A2 (0.66) | AGXTNR4A2MRGPRX4FFAR1AKR1B1 | |
| SCHEMBL6745587 | 0.74 | FFAR1 (0.48) | AGXTCFDTPSB2F11PLG | |
| SCHEMBL6667626 | 0.74 | AGXT (0.70) | AGXTNR4A2MRGPRX4FFAR1AKR1B1 | |
| SCHEMBL31580063 | 0.74 | AGXT (0.70) | AGXTNR4A2MRGPRX4FFAR1AKR1B1 | |
| SCHEMBL13739157 | 0.74 | RXRA (0.59) | CFDTPSB2F11PLGPLAU | |
| SCHEMBL23883826 | 0.72 | TDP1 (0.55) | MAPTMAPK1TDP1L3MBTL1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730783-B2 | REACTING AMINOGUANIDINE WITH CARBONYL COMPOUND TO FORM AMIDINOHYDRAZONE; REDUCTION; REACTING WITH ALKOXYAMINE; GUANIDINYLATION; ANTICOAGULANTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | disclosed |
| US-6706765-B2 | ESPECIALLY TRYPSIN-LIKE SERINE PROTEASES, SUCH AS CHYMOTRYPSIN, TRYPSIN, THROMBIN, PLASMIN AND FACTOR XA. | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-03-16 | — | — | US | disclosed |
| US-20040002539-A1 | Process for preparing aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-01 | — | — | US | disclosed |
| US-6638931-B1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-10-28 | — | — | US | disclosed |
| US-20030158252-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-08-21 | — | — | US | disclosed |
| US-6518310-B2 | Non-peptidic; inhibits trypsin-like protease, thrombin and embolus formation; anticoagulant | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-02-11 | — | — | US | disclosed |
| EP-0944590-B1 | AMINOGUANIDINES AND ALKOXYGUANIDINES AS PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2002-03-20 | — | — | EP | disclosed |
| US-20010037039-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-11-01 | — | — | US | disclosed |
| US-6235778-B1 | ANTICOAGULANTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002539-A1 | Process for preparing aminoguanidines and alkoxyguanidines as protease inhibitors | F9, PLG, MMP9 | AGXT 302/4885CFD 64/4885TPSB2 238/4885 |
| US-20030158252-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | PLG, MMP9, F9 | AGXT 322/4885CFD 82/4885TPSB2 219/4885 |
| US-20010037039-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | F9, PLG, MMP9 | AGXT 281/4885CFD 72/4885TPSB2 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.